Catabasis has shared its March 2020 update:
Catabasis provided an update regarding COVID-19 and Duchenne, FAQ’s, and shared the presentation slides from the MDA Virtual Clinical Trials Session.
In Duchenne, the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. By inhibiting NF-kB, edasalonexent has the
potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasalonexent is being developed as both a monotherapy and for use with other
therapies, including exon-skipping therapies and other dystrophin-targeted therapies in development such as gene therapy.
The Phase 3 PolarisDMD trial and GalaxyDMD open-label extension study are both ongoing. Top-line results for PolarisDMD are expected in the fourth quarter of 2020.
Catabasis is a community of experts from multiple disciplines who have come together with the common goal of bringing hope and life-changing therapies to patients and their families.
In 2008, they recognized that traditional approaches to drug discovery and development may not address the multiple underlying defects causing a disease, and founded Catabasis Pharmaceuticals. They set foot on a path forward leveraging a technology they now call their SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform. With this platform, they have engineered molecules that simultaneously modulate multiple biological targets within one or more related disease pathways – thus allowing bioactives to reach their targets more efficiently and to have greater efficacy.